Using the CD16-blocked PBMCs in an ADCC reaction against neuroblastoma cells led to a 40% reduction in the cytotoxic response against the target cells, in comparison to cell lysis with unblocked PBMCs (Fig. 5C). The gene discussed is FCGR3A; the disease is neuroblastoma.